Search results
Results from the WOW.Com Content Network
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
Thromboembolic events, such as blood clots show with high risk in COVID-19 patients in some studies. [42] Other cardiovascular complications may include heart failure, arrhythmias, and heart inflammation. [43] [44] [45] They are common traits in severe COVID-19 patients due to the relation with the respiratory system. [46]
★ Coronavirus Disease 2019 (COVID-19)—Symptoms (in en). Centers for Disease Control and Prevention (20 March 2020). Retrieved on 21 March 2020. Date: 3 March 2020: Source: Own work: Author: Mikael Häggström, M.D. Author info - Reusing images - Conflicts of interest: None Mikael Häggström, M.D. Other versions
For premium support please call: 800-290-4726 more ways to reach us
The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19. [ 211 ] [ 217 ] According to a June 2022 study, COVID‑19 vaccines prevented an additional 14.4 to 19.8 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021 ...
Tiny organ-like structures grown in the laboratory to behave like human lungs and colons can be used to rapidly screen drugs and identify those with potential as COVID-19 treatments, researchers ...
The primary data supporting the US Food and Drug Administration (FDA) emergency use authorization for molnupiravir are from MOVe-OUT, a randomized, double-blind, placebo-controlled clinical trial studying molnupiravir for the treatment of non-hospitalized participants with mild to moderate COVID‑19 at high risk for progression to severe COVID ...